Market Research Report
Cholera - Pipeline Review, H2 2020
|Published by||Global Markets Direct||Product code||246032|
|Published||Content info||62 Pages
Delivery time: 1-2 business days
|Cholera - Pipeline Review, H2 2020|
|Published: July 31, 2020||Content info: 62 Pages||
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cholera - Pipeline Review, H2 2020, provides an overview of the Cholera (Infectious Disease) pipeline landscape.
Cholera is an acute infectious disease caused by a bacterium, Vibrio cholera, which results in a painless, watery diarrhea in humans. Symptoms of cholera can begin as soon as a few hours or as long as five days after infection. Often symptoms are mild. But sometimes they are very serious. Signs and symptoms of Cholera include rapid heart rate, loss of skin elasticity, low blood pressure, thirst, muscle cramps. If not treated, this can lead to shock and death in a matter of hours.
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cholera - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Cholera (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Cholera (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Cholera and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Discovery stages are 1, 1 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 1, 6 and 2 molecules, respectively.
Cholera (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.